THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter study.

Trial Profile

THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Erdosteine (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Edmond Pharma
  • Most Recent Events

    • 01 Oct 2017 Primary endpoint (The number of acute exacerbations of COPD experienced by the patients) has been met,as published in the European Respiratory Journal.
    • 01 Oct 2017 Results published in the European Respiratory Journal
    • 30 Sep 2015 Status changed from active, no longer recruiting to completed according to results presented at the 25th Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top